Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting

Abstract

Psoriasis is a complex, chronic, and immune-mediated inflammatory disease affecting almost 2.5% of the world population. 1 Psoriasis is primarily a dermatological condition that is most often associated with other comorbidities, including psoriatic arthritis, hypertension, diabetes mellitus, obesity, psychiatric disorders, and systemic inflammation beyond the skin. Effective, safe, and long-term management of psoriasis is important in controlling skin lesions and preventing metabolic and psychiatric comorbidities. 2 New treatment

The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review

“…Demirel Öğüt (2022) 28 Obesity/BMI Ixekizumab • Of the 7 patients who lost weight, 6 achieved impressive results (PASI75).…”

“…Most of our included studies have assessed psoriasis treatment outcomes in patients with a high BMI/obesity, [25][26][27][28][29][30][32][33][34][35][36][37][38][39][40]44 which overwhelmingly highlight lower rates of achieving both PASI75 and PASI90. The majority of studies reported proportions of participants achieving PASI75, PASI90, and/or PASI100 based on BMI.…”

“… Gkalpakiotis (2021) 27 Obesity/BMI Risankizumab Higher BMI was not statistically significant for achieving worse outcomes for achieving PASI90 or PASI100, however there was a correlation between the two. Demirel Öğüt (2022) 28 Obesity/BMI Ixekizumab At week 4, PASI75 and PASI90 responses were lower in obese patients than non-obese patients (41.7% vs 78.3% and 33.3% vs 69.6%; p=0.028 and p=0.042, respectively). The same result was seen for absolute PASI scores of <2, <3, and <5 at week 4 (p=0.001), p=0.035, and p=0.045 respectively.…”

“…A total of 17 studies evaluated obesity/BMI as a cardiometabolic factor, [25][26][27][28][29][30][32][33][34][35][36][37][38][39][40]44 4 studies evaluated diabetes, 25,29,31,34 4 studies evaluated hypertension 25,29,31,34 and 4 studies evaluated lipid disorders. 25,29,31,34 Most of the studies tested drug efficacy for the IL-12/IL-23 inhibitors.…”

“…25,29,31,34 Most of the studies tested drug efficacy for the IL-12/IL-23 inhibitors. 25,33,36,[38][39][40]45 Seven papers also analyzed TNF inhibitors, 25,26,[32][33][34]37,45 5 analyzed IL-17 inhibitors 25,28,31,33,35 One study did not specify the class of the biologic and instead referred to treatment as biological agents. 29 Outcomes of each study are summarized in Table 2.…”